Novartis (NYSE:NVS – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Novartis to similar companies based on the strength of its profitability, analyst recommendations, valuation, risk, earnings, institutional ownership and dividends.
Volatility & Risk
Novartis has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Comparatively, Novartis’ peers have a beta of -0.04, indicating that their average stock price is 104% less volatile than the S&P 500.
Institutional and Insider Ownership
13.1% of Novartis shares are owned by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 0.0% of Novartis shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Novartis and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Novartis | 18.11% | 41.04% | 14.45% |
| Novartis Competitors | -2,398.26% | -203.62% | -15.08% |
Valuation and Earnings
This table compares Novartis and its peers revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Novartis | $54.53 billion | $13.98 billion | 30.89 |
| Novartis Competitors | $18.73 billion | $3.24 billion | 559.26 |
Novartis has higher revenue and earnings than its peers. Novartis is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Dividends
Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 1.9%. Novartis pays out 58.8% of its earnings in the form of a dividend. As a group, “Pharmaceuticals” companies pay a dividend yield of 3.3% and pay out 49.2% of their earnings in the form of a dividend. Novartis lags its peers as a dividend stock, given its lower dividend yield and higher payout ratio.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Novartis and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Novartis | 3 | 9 | 6 | 0 | 2.17 |
| Novartis Competitors | 7845 | 13798 | 25818 | 1039 | 2.41 |
Novartis presently has a consensus target price of $152.25, suggesting a potential downside of 5.95%. As a group, “Pharmaceuticals” companies have a potential upside of 23.92%. Given Novartis’ peers stronger consensus rating and higher possible upside, analysts clearly believe Novartis has less favorable growth aspects than its peers.
Summary
Novartis peers beat Novartis on 9 of the 15 factors compared.
Novartis Company Profile
Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company’s medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.
